Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Transcriptional Regulation of the Human Toll-Like Receptor 2 Gene in Monocytes and Macrophages This information is current as of August 3, 2017. Viola Haehnel, Lucia Schwarzfischer, Matthew J. Fenton and Michael Rehli J Immunol 2002; 168:5629-5637; ; doi: 10.4049/jimmunol.168.11.5629 http://www.jimmunol.org/content/168/11/5629 Subscription Permissions Email Alerts This article cites 39 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/168/11/5629.full#ref-list-1 Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 References The Journal of Immunology Transcriptional Regulation of the Human Toll-Like Receptor 2 Gene in Monocytes and Macrophages1 Viola Haehnel,* Lucia Schwarzfischer,* Matthew J. Fenton,† and Michael Rehli2* I n vertebrate organisms the innate branch of the immune system greatly relies on the recognition of conserved microbial structures (pathogen-associated molecular patterns (PAMPs)3). Recent studies have demonstrated an import role of members of the Toll-like receptor (TLR) family in the initiation of intracellular signaling pathways through the recognition of PAMPs (1–3). Only five years ago, the prototypic Toll protein of Drosophila—a transmembrane receptor which was initially shown to control dorsalventral patterning in the embryo—was also found to be required for antifungal responses in adult flies (4). Since then, 10 mammalian Toll homologs have been identified that contain a leucine-rich ectodomain and a conserved cytoplasmic domain shared with both chains of the IL-1R, the IL-18R, SIGRR, and MyD88, the socalled Toll/IL-1R homologous region. Both genetic and biochemical data support a common signaling pathway that finally leads to the activation of NF-B (1–3). Several studies using either TLR knockout mice or TLR mutant mouse strains have shown that mammalian TLR proteins are able to recognize specific microbial structures. Signaling cascades activated by LPS, the abundant glycolipid of the outer membrane of Gram-negative bacteria, are initiated through TLR4 (5–7). Another PAMP, bacterially derived CpG DNA, is recognized through a *Department of Hematology and Oncology, University of Regensburg, Regensburg, Germany; and †Pulmonary Center, Boston University School of Medicine, Boston, MA 02118 Received for publication October 29, 2001. Accepted for publication March 21, 2002. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work was supported by Grant Re1310/2-1 from the Deutsche Forschungsgemeinschaft (to M.R.). Sequence data from this article have been submitted to GenBank (accession nos. AF424049 –AF424053). 2 Address correspondence and reprint requests to Dr. Michael Rehli, Department of Hematology and Oncology, University Hospital, 93042 Regensburg, Germany. Email address: [email protected] 3 Abbreviations used in this paper: PAMP, pathogen-associated molecular pattern; MALP, macrophage-activating lipopeptide; TLR, Toll-like receptor. Copyright © 2002 by The American Association of Immunologists TLR9-dependent mechanism (8). TLR5 recognizes bacterial flagellin from both Gram-positive and Gram-negative organisms (9). The protein product of the TLR2 gene has been implicated in signal transduction events induced by several microbial products (e.g., peptidoglycans, lipopeptides, and lipoarabinomannans) (10 – 17). In contrast to other TLR proteins, TLR2 seems to recognize microbial patterns as a heterodimer, e.g., with TLR6 or maybe TLR1 (18). In mice, destructive mutations of TLR2 impede a normal response to lipoproteins and cause a high susceptibility to Gram-positive infection. Murine TLR2⫺/⫺ macrophages show normal responses to LPS stimulation (14). Although the genetic evidence described above strongly supports the contention that TLR4 is the predominant, if not exclusive, receptor for LPS, an additional role of TLR2 as LPS receptor is still debated. TLR2 does appear to mediate cellular activation by purified LPS from Leptospira interrogans and Porphyromonas gingivalis, which are structurally different from enteric LPS (19, 20). Expression of TLR2 in humans is restricted to a small number of cell types, including predominantly myelomonocytic cells (monocytes, macrophages, dendritic cells, and granulocytes) (21, 22). Both the basal level of TLR2 expression and its inducible regulation may influence responses to microbial infection. Accordingly, we have sought to characterize the human TLR2 promoter and to analyze those factors that govern TLR2 gene expression in human monocytes/macrophages. Interestingly, the expression of human and murine TLR2 genes is controlled by distinct, nonconserved regulatory elements. We have found that promoter sequences of both species show no significant homology and, in contrast to its murine counterpart, the human TLR2 promoter does not respond to microbial pattern-activated NF-B in monocytes and macrophages. Materials and Methods Chemicals All chemical reagents used were purchased from Sigma-Aldrich (Berlin, Germany) unless otherwise noted. Protease inhibitors are from Roche Biochemicals (Basel, Switzerland). Oligonucleotides were synthesized by TIB 0022-1767/02/$02.00 Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 This report investigates the molecular basis for tissue-restricted and regulated expression of the pattern recognition receptor Toll-like receptor (TLR)2 in human monocytes and macrophages. To define the proximal promoter, the full 5ⴕ-sequence and transcriptional start sites of TLR2 mRNA were determined. The human TLR2 gene was found to consist of two 5ⴕ noncoding exons followed by a third coding exon. Alternative splicing of exon II was detected primarily in human blood monocytes. The proximal promoter, exon I, and part of intron I were found to be located in a CpG island. Although CpG methylation of the proximal human TLR2 promoter in cell lines correlated with TLR2 repression, the promoter was unmethylated in primary cells, indicating that CpG methylation does not contribute to the cell-type specific expression of human TLR2 in normal tissues. The promoter sequence contains putative binding sites for several transcription factors, including Sp1 and Ets family members. Reporter gene analysis revealed a minimal promoter of 220 bp that was found to be regulated by Sp1, Sp3, and possibly PU.1. Interestingly, no sequence homology was detected between human and murine TLR2 promoter regions. In contrast to murine TLR2, expression of human TLR2 in monocytes/macrophages is not induced by the proinflammatory stimuli LPS or macrophage-activating lipopeptide-2, and reporter activity of the promoter was not enhanced by stimuli-induced NF-B activation in THP-1 or MonoMac-6 cells. Our findings provide an initial definition of the human TLR2 promoter and reveal profound differences in the regulation of an important pattern recognition molecule in humans and mice. The Journal of Immunology, 2002, 168: 5629 –5637. 5630 Molbiol (Berlin, Germany). Antisera for supershift analyses were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Cells RNA preparation, RT-PCR, and Northern analysis Total RNA was isolated from different cell types by the guanidine thiocyanate/acid phenol method (23). Two micrograms of total RNA from either cell type was reverse transcribed using oligo(dT) primer and Superscript II (Life Technologies). Primer positions and sizes for the amplified fragments of TLR2 and -actin are indicated (see Fig. 2). PCR conditions were optimized to assure that the amplification was still exponential at the indicated cycle numbers. The amplified products were sequenced to confirm their identity. For Northern analysis, total RNA (10 g/lane) was separated by electrophoresis on 1% agarose/formaldehyde gels and transferred to nylon membranes (Magna NT; Micron Separations, Westboro, MA). Hybridization was performed using a 32P-labeled cDNA probe of a 1500-bp restriction fragment of human TLR2 (random primed labeling by Hartmann Analytics, Braunschweig, Germany). Autoradiography was performed at ⫺70°C and bands were scanned with a personal densitometer (Molecular Dynamics, Sunnyvale, CA). RNA ligase-mediated RACE-PCR Ten micrograms of total RNA from purified human blood monocytes was used for cDNA synthesis with the FirstChoice RLM-RACE kit (Ambion, Austin, TX). The following TLR2-specific primers were used to amplify full-length 5⬘ cDNA fragments of human TLR2: hTLR2-OUT (5⬘-AA GATCCTGAGCTGCCCTTGC-3⬘), hTLR2-IN (5⬘-CCAAGACCCACAC CATCCAC-3⬘). PCR products were cloned into pCR2.1-TOPO (TOPO Cloning kit; Invitrogen) and inserts from 13 individual plasmid-containing bacterial colonies were amplified by PCR and directly sequenced. Plasmid construction and purification A 2.8-kb genomic fragment of the human TLR2 promoter was amplified from a BAC clone (Incyte Genomics, Palo Alto, CA) containing the human TLR2 gene using the Expand High Fidelity PCR system (Roche Biochemicals) and the primers 5⬘-CGGACATACGGACATCTGTGC-3⬘ (sense) and 5⬘-CTGGGAGAACTCCGAGCAGTC-3⬘ (antisense). Primer sequences were derived from a TLR2-containing BAC sequence deposited in the GenBank database (GenBank accession no. AC013303). The obtained PCR fragment was inserted into the plasmid vector pCR2.1-TOPO (TOPO Cloning kit; Invitrogen) and completely sequenced. An EcoRI-digested, Klenow-treated, and BglII-digested 2.7-kb genomic PCR fragment of the human TLR2 proximal promoter was subcloned into the BglII and Klenowtreated HindIII restriction sites of pGL3-B (Promega, Madison, WI) and sequenced. Deletions of this construct were generated using the internal XbaI (⫺2070), HindIII (⫺370), PvuII (⫺220), PmaC I (⫺64), or SmaI (⫹24) restriction sites of the TLR2 promoter. The (⫺45) deletion was PCR-amplified from the 2.7-kb construct using primer ⌬SP-S (5⬘AGTCGCTAGCGTTCCCGCACCCCAGA-3⬘) and vector primer GL-2 and subcloned into BglII/NcoI sites of pGL3-B. Mutations of two putative Sp1 sites were done by PCR-mediated mutagenesis using primers S1-S (5⬘-GTGGAAGGTTAGGTTCCCGCACCCC-3⬘), S1-AS (5⬘-AACCTA ACCTTCCACGGGGCAC-3⬘), S2-S (5⬘-GCTCACGGTCAAGGTTAG GAGCC-3⬘), and S2-AS (5⬘-CCCAGCAGGCTCCTAACCTTGACC-3⬘). Mutation of a putative Ets/PU.1 site in the (⫺64) construct was done using primer PU-S (5⬘-TCTTACGCGTGCTAGGTGCCCCGACGAAGGGGC GG-3⬘). Changed nucleotides in primer sequences are in boldface and italics. Mutated PCR fragments were back-cloned into pGL3-B. For transient transfections, plasmids were isolated and purified using the Endofree Plasmid kit (Qiagen, Hilden, Germany). DNA sequence analysis The cDNA sequencing was done by Dye Deoxy Terminator Cycle Sequencing (PE Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions and sequences were analyzed on the PE Applied Biosystems DNA Sequencing System (model 373A). Transient DNA transfections MonoMac-6 cells were transfected using DEAE-dextran. A total of 5 ⫻ 105 MonoMac-6 cells per milliliter were seeded into tissue culture flasks the day before transfection. On the next day, 6 ml cell suspension was washed twice with suspension TBS (STBS) solution (25 mM Tris䡠Cl, pH 7.4, 137 mM NaCl, 5 mM KCl, 0.6 mM Na2HPO4, 0.7 mM CaCl2, and 0.5 mM MgCl2) and pelleted. One microgram of reporter plasmid and 62.5 ng renilla control vector were mixed with DEAE-dextran (400 g/ml) in 130 l STBS buffer and immediately added to the pelleted MonoMac-6 cells. The cells were incubated at 37°C for 20 min, washed twice with STBS, resuspended, and cultured in complete RPMI medium. Where indicated, LPS (100 ng/ml) or MALP-2 (400 U/ml) was added to the cultures 4 h before harvesting. The cell lines THP-1 and HeLa were transfected as previously described (24). The transfected cell lines were cultivated for 48 h and harvested, and cell lysates were assayed for firefly and renilla luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) on a Sirius luminometer (Berthold, Nashua, NH). Firefly luciferase activity of individual transfections was normalized against renilla luciferase activity. Drosophila S2 Schneider cells were transfected using Effectene reagent (Qiagen) according to the manufacturer’s instructions. Briefly, 4 ⫻ 105 Schneider cells were cells were cotransfected using 10 l Effectene reagent and 1.5 g total DNA (1 g of reporter plasmid, 0.25 g of individual expression plasmids). Duplicate transfections were harvested after 48 h and cell lysates were assayed for firefly luciferase activity using the Luciferase Reporter Assay System (Promega). Firefly luciferase activity of individual transfections was normalized against protein concentration measured using a BCA assay (Sigma-Aldrich). Nuclear extracts and EMSA Nuclear extracts were prepared with a variation of the method of Osborn et al. (17). All buffers used contained 1 mM Na3VO4 and a mixture of protease inhibitors (2 g/ml aprotinin, 0.5 g/ml leupeptin, 1 g/ml pepstatin, 20 g/ml bestatin, 5 g/ml E46, 50 g/ml antipain, 100 g/ml chymostatin). Double-stranded oligonucleotides were labeled with [␣-32P]deoxycytidine 5⬘-triphosphate using Klenow DNA polymerase. A double-stranded oligonucleotide containing the proximal Sp1 motif from the human TLR2 promoter (Tlr2-Sp) as well as a consensus Sp1 motif (5⬘-CGATTCG ATCGGGGCGGGGCGAGC-3⬘) were used as cold competitor. The binding reaction contained 2.5 g of nuclear extract protein, 0.5 g of poly(dI/ C), 20 mM HEPES (pH 7.9), 60 mM KCl, 1 mM DTT, 1 mM EDTA (pH 8), 5% glycerol, and 20 nmol of probe DNA in a final volume of 10 l. Antisera used in supershift analyses were added after 15 min and samples were loaded onto polyacrylamide gels after standing at room temperature for a total of 30 min. Buffers and running conditions used have been described. Gels were fixed in 5% acetic acid, dried, and autoradiographed. DNA preparation and bisulfite sequencing Genomic DNA from various cell types was prepared using the Blood and Cell Culture DNA Midi kit from Qiagen. Modification of DNA with sodium bisulfite (25) was performed as follows. A total of 5 g genomic DNA in 50 l 10 mM Tris䡠Cl, pH 8.0, 1 mM EDTA were denatured with 5.5 l NaOH (3 M) at 37°C for 15 min. After the addition of 540 l sodium bisulfite (3.8 M) and 15 l hydrochinone (0.4 M), samples were mixed, divided into six aliquots, and covered with mineral oil. Incubation was performed in a PCR cycler (five cycles at 95°C for 3 min and 55°C for 57 min). Samples were recombined after treatment and DNA was recovered using Wizard (Promega) in 100 l H2O and desulfonated by the addition of 11 l NaOH (3 M) and subsequent incubation at 37°C for 15 min. The Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 PBMCs were separated by leukapheresis of healthy donors, followed by density gradient centrifugation over Ficoll/Hypaque (Amersham Biosciences, Freiburg, Germany). Monocytes were isolated from PBMC by countercurrent centrifugal elutriation in a J6 M-E centrifuge (Beckman, München, Germany) as previously described. Monocytes were ⬎90% pure as determined by morphology and expression of CD14 Ag. Isolated monocytes were cultured in low-endotoxin RPMI 1640 medium (Biochrom, Berlin, Germany) supplemented with vitamins, antibiotics, pyruvate, nonessential amino acids (all from Life Technologies, Eggenstein, Germany), 5 ⫻ 10⫺8 M 2-ME, and 2% human pooled AB-group serum on tissue culture plates for the indicated time periods. The human monocytic cell line THP-1 was grown in RPMI 1640 medium supplemented with vitamins, antibiotics, pyruvate, and nonessential amino acids, plus 10% FCS (Life Technologies). The human monocytic cell line MonoMac-6 was grown in complete RPMI medium as above, with the addition of 1% OPI media supplement. The human cervical carcinoma cell line HeLa was maintained in DMEM plus 10% FCS. Where indicated, cells were treated with 100 ng/ml purified LPS from Salmonella abortus equi (a gift from C. Galanos, Max-Planck-Institut, Freiburg, Germany) or with 400 U/ml of the mycoplasmal lipopeptide macrophage-activating lipopeptide (MALP)-2 (a gift from P. Mühlradt, Gesellschaft für Biotechnologische Forschung, Braunschweig, Germany). The latter was kept as a stock solution of 1 mg/ml (4 ⫻ 108 U/ml) in water-2-propanol (1:1, v/v) at 4°C and was diluted as described. Drosophila S2 Schneider cells (a gift from Dr. W. Falk, Internal Medicine I, University Hospital, Regensburg, Germany) were cultivated in Schneider’s Drosophila medium (Invitrogen, Karlsruhe, Germany). STRUCTURE AND REGULATION OF THE HUMAN TLR2 GENE The Journal of Immunology DNA was then precipitated using ammonium acetate and ethanol and resuspended in 50 l 10 mM Tris䡠Cl, pH 8.0, 1 mM EDTA. A total of 5 l of DNA was amplified in individual nested PCR for both strands using the following primers: sense strand (first round), Ss1 (5⬘-GTTTTAAGAAAA TATTGGTTGGG-3⬘) and Sas1 (5⬘-CAAAAACTAAAAACCCAAATA CAAC-3⬘); sense strand (first round), Ss2 (5⬘-TGGGTATTTAGTTTT TTTTGTGG-3⬘) and Sas2 (5⬘-AAAAAACTCCRAACAATCACC-3⬘); antisense strand (first round), ASs1 (5⬘-CTTTCCCTATAATTACCAA TCCC-3⬘) and ASas1 (5⬘-TAGGAAGGGGTGTAGAGAGATT-3⬘); antisense strand (second round), ASs2 (5⬘-CAAACCCCCAACTCTCTTC-3⬘) and ASas2 (5⬘-AGAATTTYGAGTAGTTATTTGAGAGAA-3⬘). Products from the second round of nested PCR were precipitated and sequenced. Unmethylated cytosine residues are converted into thymidine residues during the bisulfite treatment and subsequent PCR amplification, whereas methylated cytosine residues are protected. Results Isolation of full-length TLR2 transcripts and structure of the human TLR2 gene Alternative splicing of the human TLR2 The majority of 5⬘ fragments amplified from monocytes by RLMRACE-PCR was found to lack the sequence of exon II, indicating the presence of alternatively spliced forms of TLR2. To analyze the presence of splicing forms in different TLR2-expressing cell types, RT-PCR with specific primers flanking the region between exons I and III of the human TLR2 gene was performed. As shown in Fig. 2A, the obtained band pattern varied among cell types and individuals. With the exception of monocytes, all cell types primarily expressed the longest transcript containing exon I, II, and III. In monocytes three distinct products were detectable; however, the relative distribution of transcripts was dependent on the individual donor. Sequencing of cloned fragments from monocytes revealed five different splicing variants and the usage of two alternative splice acceptor sites and three splice donor sites in exon II (see Fig. 1B). All splice junctions contained the expected GT splice donor and AG splice acceptor. The shortest fragment completely lacked exon two, and the three intermediate fragments were using acceptor site I/donor site I, acceptor site II/donor site II, or acceptor site III/donor site II (see Fig. 1B). All splicing variants contained the complete sequence of exon III and are predicted to code for one TLR2 protein. Interestingly, splicing of TLR2 mRNAs rapidly changed upon adherence of freshly isolated monocytes. As shown for two individual donors in Fig. 2B, the ratio of short and long splice variants is altered during monocyte differ- entiation in vitro, with the long splice variant being predominant after adherence of monocytes for only 3 h. Activity of the proximal human TLR2 promoter in myeloid THP-1 and nonmyeloid HeLa cells Published Northern blot analyses suggest that human TLR2 is predominantly expressed in spleen, lung, and peripheral blood leukocytes (26, 27). Monocytes, monocyte-derived dendritic cells, and granulocytes were identified as the major TLR2-expressing cells in human blood (21, 22). To further analyze mechanisms regulating myeloid expression of TLR2, we cloned fragments of the 5⬘ proximal promoter region of the human TLR2 gene, ranging from 2.7 kb to 100 bp upstream of the ATG-start codon, into a luciferase reporter plasmid (Fig. 3). Transient transfection analysis was performed in the monocytic cell line THP-1 and nonmyeloid cell line HeLa (cervical carcinoma). Luciferase activities were normalized for transfection efficiency by cotransfection with a renilla construct, and results for individual cell lines were compared relative to the activity of a CMV promoter-driven construct that was used as a positive control. As shown in Fig. 3, deletion analysis localizes a region directing maximal reporter gene expression in THP-1 cells to ⬃220 bp proximal to the major transcriptional start site. Significant reporter activity was also measured in HeLa cells, which do not express TLR2 (data not shown), indicating that additional regulatory elements are involved in cell type-specific expression of the human TLR2 gene. The proximal promoter region of human TLR2 is distinct from murine TLR2 The 5⬘ proximal region of human TLR2 lacks TATA boxes or consensus initiator sequences. Instead it contains several GC-rich regions that are often found in housekeeping genes and may determine transcriptional initiation (Fig. 1B). Within the ⫺220 bp region, putative binding sites for Sp1 family transcription factors and an E-box element were identified using computational analysis (TRANSFAC database). In addition, purine-rich elements with a 5⬘-GGAA-3⬘ core on either strand were detected, which could serve as binding sites for Ets family transcription factors. The sequence of the murine TLR2 promoter has been deposited in GenBank (accession no. AF252535), and a recent publication described the inducible regulation of murine TLR2 by NF-B and STAT5 (28). Whereas the coding regions of human and murine TLR2 share a high degree of homology (75%), sequence comparison using a ClustalW algorithm did not reveal a significant level of homology (6 –10%) between the proximal promoter regions and exons I and II of mouse and human TLR2 genes. This is in sharp contrast to the strong homology (61–77%) of corresponding regions in human and murine TLR4 genes and indicates that TLR2 may be regulated differently in both species. Indeed, differences in TLR2 expression have been observed in mice and humans. Northern blot analysis of various mouse tissues by Matsuguchi et al. (29) revealed the highest expression of TLR2 in lung and spleen followed by thymus and brain. Tlr2 expression was also observed in murine adipose tissue (30). However, no (or very low) TLR2 expression was detected in mouse blood (29). In human tissues, the strongest TLR2 expression was detected in peripheral blood leukocytes, followed by spleen and lung; no expression was detected in human thymus (26, 27). TLR2 expression in T cells was observed only in mice, not in humans (22, 29). These differential expression patterns are likely due to the differences in TLR2 genomic sequences and regulatory context in mice and humans. As indicated in Fig. 1A, a copy of exon III ( psIII) is located Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 As an initial step to characterize regulatory regions of the human TLR2 gene, we determined the transcriptional start sites and the full-length sequence of TLR2 transcripts in human monocytes, which express relatively high levels of TLR2 mRNA. PCR fragments of full-length 5⬘ ends were obtained by RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE), a method which allows the selective amplification of capped, full-length transcripts. PCR fragments were cloned and sequenced as described in Materials and Methods. Thirteen individual fragments were specific for human TLR2, extending the longest published cDNA sequence (GenBank accession no. AF051152) for an additional 110 bp. The positions and relative abundance of transcription start sites are indicated in Fig. 1B. The public human genome database was searched for sequenced BAC clones containing the human TLR2 gene, and a 77-kb BAC sequence was identified which contained the entire TLR2 gene (GenBank accession no. AC013303). Comparison of genomic and cDNA sequences revealed that the additional 5⬘ sequence corresponds to a novel first exon. The structure of the complete human TLR2 gene is shown in Fig. 1A. 5631 5632 STRUCTURE AND REGULATION OF THE HUMAN TLR2 GENE ⬃4 kb upstream of the human TLR2 gene. The presence of a noncoding pseudogene indicates that, in humans, a duplicate of the coding exon III may have been placed into a different regulatory context during evolution. Sp1 and Sp3 bind and activate the proximal human TLR2 promoter Binding sites for Sp1 family members are implicated in the regulation of several macrophage-specific genes (31–34). Several GCrich sequences and putative binding sites for Sp1 family transcription factors are present in the proximal TLR2 promoter. As shown Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 FIGURE 1. The human TLR2 gene. A, Physical map of the human TLR2 gene. Boxes mark the position of exons I–III. In-frame start- and stop-codons are indicated. The box marked psIII indicates the position of a region highly homologous to the third exon of TLR2. B, Promoter sequence and intron flanking sequences of exons I–III. Potential binding sites in the proximal promoter for transcription factors are over- and underlined. Nucleotide sequences of exons are in boldface and italics and transcription start sites are marked with arrows. The number of fragments obtained for each start site are given above the arrows. Start sites of the published sequences are indicated with their respective GenBank accession numbers. CpGs are in bold lettering. The numbers (1–20) below CpGs in the proximal promoter region refer to the numbering in Table I. Alternative splice donor and acceptor sites in exon II are indicated. All splice junctions contain the expected GT splice donor and AG splice acceptor. The predicted N-terminal amino acid sequence in exon III is also shown. in Fig. 4, specific binding of Sp1 and Sp3 to the proximal putative Sp1 site was observed in EMSA using THP-1 nuclear extracts as well as HeLa cell nuclear extracts (data not shown). The oligonucleotide used in EMSA also contained a putative binding site for members of the Ets family of transcription factors, which includes PU.1, an important regulator of macrophage-specific genes. However, no specific binding of recombinant PU.1 was detectable in EMSA, and the addition of PU.1 Ab in supershift experiments had no effect on the observed band pattern (data not shown). The proximal and a putative distal Sp1 site were mutated to analyze their functional significance in reporter assays. In monocytic THP-1 The Journal of Immunology cells, mutation of the proximal site showed a marked decrease in reporter activity compared with the wild-type promoter (Fig. 5A), indicating that this element is required for full reporter activity. Mutation of the putative distal site had no impact on reporter gene activity. We also deleted and mutated the putative Ets/PU motif immediately upstream of the proximal Sp1 site to determine whether this element accounts for the residual activity in the ⫺64 promoter. As shown in Fig. 5B, mutation of this site had no effect on the activity of the ⫺64 promoter. Also, deletion of both Sp1 and putative Ets elements in the ⫺45 promoter resulted in a similar decrease in reporter activity as observed using the ⫺64 promoter with a mutated Sp1 site. The results indicate the presence of ad- FIGURE 3. Deletion analysis of the human TLR2 promoter. Each deletion mutant was transiently transfected into myeloid THP-1 cells and nonmyeloid HeLa cells as described in Materials and Methods. Luciferase activity is relative to a CMV promoterdriven positive control and values are the mean ⫾ SD obtained from at least three independent experiments. FIGURE 4. Sp1/3 binding to a proximal binding site of the human TLR2 promoter. Labeled TLR2-Sp oligonucleotide containing the putative proximal Sp1 site as well as an adjacent putative Ets site was used in EMSA with THP-1 nuclear proteins. Addition of unlabeled oligonucleotides for competition analysis or antisera against Sp-1 family transcription factors is indicated above each lane. Arrows indicate Sp1/3-containing complexes, SS indicates Ab supershifts, and ⴱ indicates unspecific complexes. ditional elements important for promoter activity downstream of the proximal Sp1 site. To test the ability of Sp1 and Sp3 to transactivate the TLR2 promoter, cotransfection experiments were performed in Drosophila Schneider cells, which lack endogenous expression of Sp1 family transcription factors. As the promoter also contains several putative binding sites for Ets family transcription factors, an expression plasmid coding for PU.1, which is an important regulator of macrophage-specific genes, was also tested for its ability to transactivate the TLR2 promoter in combination with Sp1 family members. A representative reporter gene analysis is Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 FIGURE 2. Detection of alternative spliced TLR2 transcripts. RT-PCR with total RNA from monocytes (four different donors), in vitro differentiated macrophages, and myeloid cell lines MonoMac-6, THP-1, and U937 (A) or freshly isolated monocytes (0 h) and monocytes cultured for 3 h, 24 h, and 7 days (B) using primers located in exon I (87S: 5⬘-GTGACT GCTCGGAGTTCTCCC-3⬘) and exon III (751AS: 5⬘-GTCCATATTTC CCACTCTCAGG-3⬘). The amplified fragments were separated by agarose gel electrophoresis along with molecular mass markers and stained with ethidium bromide. The size and composition of each detected fragment is indicated. 5633 5634 shown in Fig. 6. In contrast to the ⫹24 promoter, which was minimally activated by Sp1, Sp3, or PU.1, the ⫺220 promoter was strongly induced by Sp1. Sp3 and PU.1 alone only weakly activated the ⫺220 promoter; however, in combination a significant induction was observed. Both Sp3 and PU.1 further increased Sp1mediated activation of the proximal TLR2 promoter construct. The human TLR2 promoter is not directly induced by microbial pattern-activated NF-B The regulation of pattern recognition receptors by inflammatory cytokines or bacterial products, e.g., LPS, is of particular importance for innate immune mechanisms. In mice, TLR2 is rapidly up-regulated by multiple proinflammatory stimuli, including IL1, TNF, GM-CSF, and LPS (35). The activity of its promoter is induced by LPS and the induction is dependent on NF-B- and FIGURE 6. Cotransfection analysis in Drosophila Schneider cells. Two TLR2 promoter reporter constructs—TLR2-(⫺220) containing the minimal promoter and TLR2-(⫹24) containing only parts of exon I without relevant promoter sequences—were cotransfected with expression plasmids for Sp1, Sp3, and PU.1 into Drosophila Schneider cells as described Materials and Methods. Relative luciferase activities from a representative experiment (of three) relative to the control transfection (without expression plasmids) are shown STAT5-binding sites (28). Therefore, we investigated whether the human TLR2 promoter would respond to two proinflammatory stimuli: LPS (a known ligand for TLR4) and mycoplasmal lipopeptide MALP-2 (a known ligand for TLR2/TLR6). Initially, transient transfections were performed in THP-1 cells with and without stimulation for 4 h. Neither TLR2 construct was significantly induced by any of the two stimuli, whereas a NF-B-responsive control plasmid was markedly induced in response to LPS or MALP-2 challenge (data not shown). We repeated the same experimental setup with MonoMac-6 cells, which secrete comparable cytokine levels upon activation as primary monocytes. As shown in Fig. 7, the NF-B-inducible endothelial-leukocyte adhesion molecule promoter was markedly induced in response to LPS or MALP-2 challenge. However, neither the full-length nor the ⫺220 construct was activated by either stimulus (Fig. 7). In Northern blot analyses, endogenous TLR2 mRNA levels were also not affected by LPS treatment of human THP-1 or MonoMac-6 cell lines (data not shown). Published data on TLR2 expression in LPSstimulated human monocytes are conflicting. Some authors claimed that LPS induces TLR2 expression in human monocytes (21, 36), whereas others showed that TLR2 is not induced (22). To reinvestigate this issue, Northern blot analysis was performed on total RNA from freshly isolated monocytes and in vitro differentiated macrophages treated or untreated with LPS or MALP-2. As shown in Fig. 8, TLR2 expression was up-regulated in monocytes after 3 h of adherence in the presence of serum. No additional induction of human TLR2 was observed in LPS- or MALP-2treated monocytes. During the differentiation of untreated cells, TLR2 expression was down-regulated after 24 h. In stimulated monocytes, higher levels of TLR2 expression were sustained. Little or no induction of TLR2 mRNA was observed in LPS- or MALP-2-treated adherent monocyte-derived macrophages (Fig. 8B). Our observations are in line with the seemingly conflicting published data. Muzio et al. (22) compared monocytes treated or untreated with LPS after 3 h and also observed no induction of TLR2 mRNA by LPS treatment. Yang et al. (21) detected an induction of TLR2 mRNA after 16 h, which probably corresponds to the differences we observed after 24 h. Finally, Visintin et al. (36) were detecting an increase of TLR2 mRNA after LPS treatment compared with freshly isolated monocytes; however, they failed to compare the induced mRNA levels with untreated adherent monocytes. FIGURE 7. TLR2 reporter activity in MonoMac-6 cells upon LPS or MALP-2 stimulation. MonoMac-6 cells were transfected with the indicated plasmids. Four hours before harvesting the cells, cells were treated with LPS (100 ng) or sMALP-2 (400 U) or left untreated as described in Materials and Methods. Induction of luciferase activity is shown relative to activities for untreated cells. Values are the mean ⫾ SD obtained from three independent experiments. Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 FIGURE 5. Effect of Sp1 binding site mutations on TLR2 promoter activity. Mutations of putative Sp1 (A and B) or Ets (B) binding sites as well as a deletion of the proximal Ets/Sp1 motif were introduced in reporter constructs TLR2-(⫺220) (A) and TLR2-(⫺64) (A and B) and transiently transfected into monocytic THP-1 cells as described in Materials and Methods. Luciferase activities are relative to the wild-type constructs and values are the mean ⫾ SD obtained from four to six independent experiments. STRUCTURE AND REGULATION OF THE HUMAN TLR2 GENE The Journal of Immunology 5635 Discussion In normal tissues, CpG methylation is not involved in tissue-specific TLR2 promoter activity Sequence analysis of the human TLR2 gene revealed that the proximal promoter, exon I, and portions of intron I are located within a CpG island (see Fig. 9). Methylation of CpG motifs has been described as a repression mechanism active in X chromosome inactivation, genomic imprinting, and silencing of mobile elements and has also been implicated in tissue-specific repression of genes (37). To investigate a possible effect of CpG methylation in the tissue-restricted expression of human TLR2, the methylation status of the proximal TLR2 promoter was analyzed by bisulfite sequencing. DNA from various cell lines, primary cell types, and different tissues was amplified and sequenced after bisulfate treatment. Whereas the promoter was unmethylated in normal tissues and primary cell types regardless of the transcriptional activity of the gene, almost complete CpG methylation was detected in several cell lines that do not express TLR2 (Table I). Therefore, CpG methylation is probably not involved in the tissue-specific regulation of human TLR2 in normal cells. In tumors, e.g., leukemia cells such as U937, CpG methylation of the proximal promoter may be involved in down-regulation of TLR2 expression. FIGURE 9. CpG content of the human TLR2 gene. A, Distribution of CpG sites in a 10,000-bp fragment of the human TLR2 gene. Exons I and II are represented as boxes, and an arrow marks the transcription start site. B, CpG island of the promoter region exploded. Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 FIGURE 8. Northern analysis of TLR2 expression in monocytes and macrophages. Total RNA was isolated from freshly isolated human blood monocytes (MO), monocytes adherent for 3 h or 24 h (A), and in vitro differentiated macrophages either untreated or treated with LPS (100 ng) or sMALP-2 (400 U) at 0 h (B) for the indicated time periods. The blots were hybridized with a 32P-labeled TLR2 cDNA. The ethidium bromide staining is shown as a control for mRNA loading. In this study we investigated the transcriptional regulation of TLR2 in human monocytes/macrophages. We determined the fulllength sequence and transcriptional start sites of human TLR2 and identified alternatively spliced forms of human TLR2 mRNA in human monocytes. Furthermore, we performed an initial characterization of trans-acting factors controlling the expression of human TLR2 and defined a minimal proximal promoter that confers maximal reporter activity in human monocytic THP-1 cells. We also show that human and murine TLR2 genes are regulated by structurally different promoters, which may explain the different expression patterns observed in both species. As its murine homolog, the human TLR2 gene is composed of three exons. The first and second exons are noncoding, and the complete open reading frame is located on exon III. Alternative splicing of exon II was primarily detected in human monocytes, generating up to five different mRNA species. The shortest splicing form completely lacked exon II. The other four variants contained exon II, although it was spliced at different acceptor and donor sites. Interestingly, the relative abundance of TLR2 splicing forms varied among individuals tested, and the short form of TLR2 was detectable only in freshly isolated blood monocytes. Adherence of monocytes to tissue culture plates rapidly and selectively induces transcription of the long slice variant. In theory, alternative splicing does not change the putative open reading frame; all mRNA isoforms are predicted to encode identical protein products. However, it is possible that differences in the 5⬘ untranslated sequences influence the stability of the mRNA transcript or mRNA secondary structure (e.g., hairpin loop formation), which may in turn affect the extent of TLR2 protein translation. Further investigations will be needed to clarify these issues. The 5⬘ regulatory region of TLR2 is contained in a CpG island. Similar to many housekeeping genes and several tissue-restricted genes, the proximal TLR2 promoter was completely unmethylated in normal tissues, which excludes methylation of promoter CpGs as a mechanism for regulating TLR2 expression in normal cells. However, CpG methylation of the proximal promoter region was detected in several tumor cell lines and correlated with undetectable TLR2 expression. Interestingly, TLR2 agonists have been shown to deliver a proapoptotic signal (38, 39). Therefore, transcriptional inactivation of TLR2 expression by aberrant methylation of the TLR2 promoter may represent an advantage for tumor cell survival. Further investigations shall clarify a role of TLR2 promoter methylation in growth and survival of tumors (e.g., leukemias). Expression of human TLR2 transcripts has primarily been detected in myeloid cells (monocytes, macrophages, dendritic cells, and granulocytes) (21, 22). The 5⬘ proximal region of the human TLR2 gene lacks a TATA box and instead contains several GCrich regions, which may be involved in transcriptional initiation. In reporter assays, the TLR2 promoter was strongly active in THP-1 cells but also had significant activity in HeLa cells, which do not express endogenous TLR2 message. This indicates that additional regulatory elements are involved in the observed myeloid-specific regulation of human TLR2. Our data suggest that Sp1 family transcription factors play an important role in the activation of the proximal TLR2 promoter. Although ubiquitously expressed, Sp1 family transcription factors have been implicated in the regulation of several myeloid-specific genes (31–34), most likely in collaboration with more tissue-restricted transcription factors. For example, the transcription factor PU.1 was shown to be required for the optimal expression of a growing number of myeloid-specific genes. Accordingly, PU.1 was able to collaborate with Sp3 and to 5636 STRUCTURE AND REGULATION OF THE HUMAN TLR2 GENE Table I. CpG methylation of the proximal TLR2 promotera CpG No.b Cells 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 mRNAc MO (I) MAK (I) Dendritic cells (I) B cells T cells MonoMac-6 THP-1 U937 HeLa (epithelial) HaCaT (keratinocyte) HepG2 (hepatocellular) Mel Im (melanoma) HMEC (endothelial) 0 0 0 0 0 0 0 4 4 4 4 0 0 0 0 0 0 0 0 0 4 4 4 4 0 4 0 0 0 0 0 0 0 4 4 4 4 0 0 0 0 0 0 0 0 0 4 4 4 2 0 0 0 0 0 0 0 0 0 4 4 4 4 0 0 0 0 0 0 0 0 0 2 4 1 2 0 0 0 0 0 0 0 0 0 2 4 2 4 0 0 0 0 0 0 0 0 0 2 4 2 2 0 0 0 0 0 0 0 0 0 2 4 1 2 0 0 0 0 0 0 0 0 0 2 4 2 2 0 0 0 0 0 0 0 0 0 2 4 2 2 0 0 0 0 0 0 0 0 0 2 4 2 2 0 0 0 0 0 0 0 0 0 2 4 4 4 0 4 0 0 0 0 0 0 0 2 4 4 4 0 0 0 0 0 0 0 0 0 2 4 4 4 0 0 0 0 0 0 0 0 0 2 4 4 4 0 0 0 0 0 0 0 0 0 2 4 4 4 0 0 0 0 0 0 0 0 0 2 4 4 4 0 0 0 0 0 0 0 0 0 2 4 4 4 0 0 0 0 0 0 0 0 0 2 4 4 4 0 0 ⫹ ⫹ ⫹ ⫺ ⫺ ⫹ ⫹ ⫹/⫺ ⫺ ⫺ ⫺ ⫹/⫺ ⫹/⫺ a lesser extent with Sp1 to transactivate the TLR2 promoter in Drosophila Schneider cells. Although the exact binding sites for PU.1 still need to be determined, these initial experiments suggest that PU.1 also participates in the transcriptional regulation of TLR2 in humans. The sequence of the murine TLR2 promoter has recently been published by two groups. In contrast to human and murine TLR4, which share homologous promoter regions, the promoters of human and murine TLR2 were not conserved during evolution. We were unable to detect a significant level of homology of human and murine 5⬘ upstream sequences or 5⬘ untranslated regions, indicating that the coding third exon has been placed into a different genetic context in mice and humans. The different regulatory sequences provide the most likely explanation for the observed differences in TLR2 tissue distribution, e.g., T cell expression of TLR2 in mice but not in humans. The different regulation of TLR2 in myeloid cells of both species may be of particular importance. In mice, TLR2 expression is low or undetectable in blood cells and is strongly induced by proinflammatory cytokines or microbial patterns (e.g., LPS). Accordingly, binding sites for NF-B and STAT5 in the murine TLR2 promoter have been implicated in the rapid induction of TLR2 expression by proinflammatory stimuli in murine macrophages. However, in humans, the highest constitutive levels of TLR2 expression have been observed in peripheral blood leukocytes. In human monocytes, TLR2 expression is further up-regulated after adherence to tissue culture plates, but no additional induction was observed after short-term stimulation with bacterial products LPS or MALP-2. TLR2 expression is down-regulated in adherent monocytes after 24 h of culture, whereas monocytes stimulated with LPS or MALP-2 appear to express higher levels of TLR2. Activation of purified human blood monocytes with TLR agonists is known to inhibit their differentiation into mature macrophages, which is normally accompanied by down-regulation of TLR2 expression. This presumably leads to sustained higher levels of TLR2 mRNA in activated monocytes after 24 h of culture. In addition, marginal to no induction of TLR2 was observed in monocyte-derived macrophages. This is in sharp contrast to the highlevel TLR2 induction in stimulated mouse macrophages (35). In conclusion, our observations suggest that the human TLR2 gene is regulated by Sp1 family members, probably in collaboration with the Ets family transcription factor PU.1. Additional elements (e.g., tissue-specific enhancers and silencers) are likely to contribute to the regulation of TLR2 and are the subject of further studies. In addition, our study identifies fundamental differences in the transcriptional regulation of TLR2 in mice and humans. The observed differences in basal cell type-specific and -induced expression of TLR2 may significantly influence the immune response of both species to bacterial challenges. Acknowledgments We are grateful to Dr. Guntram Suske and Dr. Susanne Müller for providing Sp1 family and PU.1 expression vectors for Drosophila Schneider cells and to Dr. Peter Mühlradt for providing sMALP-2. We are also grateful to Dr. Daniel Salamon for his help with the CpG-methylation analysis. We acknowledge the excellent technical assistance of Sabine Pape. We thank Dr. Stefan Krause for suggestions and members of our laboratories for helpful discussions. References 1. Aderem, A., and R. J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406:782. 2. Krutzik, S. R., P. A. Sieling, and R. L. Modlin. 2001. The role of Toll-like receptors in host defense against microbial infection. Curr. Opin. Immunol. 13: 104. 3. Medzhitov, R., and C. Janeway, Jr. 2000. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173:89. 4. Gay, N. J., and F. J. Keith. 1991. Drosophila Toll and IL-1 receptor. Nature 351:355. 5. Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749. 6. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. V. Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085. 7. Qureshi, S. T., L. Lariviere, G. Leveque, S. Clermont, K. J. Moore, P. Gros, and D. Malo. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189:615. 8. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740. 9. Hayashi, F., K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J. K. Eng, S. Akira, D. M. Underhill, and A. Aderem. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099. 10. Flo, T. H., O. Halaas, E. Lien, L. Ryan, G. Teti, D. T. Golenbock, A. Sundan, and T. Espevik. 2000. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J. Immunol. 164:2064. 11. Lien, E., T. J. Sellati, A. Yoshimura, T. H. Flo, G. Rawadi, R. W. Finberg, J. D. Carroll, T. Espevik, R. R. Ingalls, J. D. Radolf, and D. T. Golenbock. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274:33419. 12. Opitz, B., N. W. Schroder, I. Spreitzer, K. S. Michelsen, C. J. Kirschning, W. Hallatschek, U. Zahringer, T. Hartung, U. B. Gobel, and R. R. Schumann. Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 a Methylation of promoter CpGs was determined using the bisulfite method as described in Materials and Methods. The degree of methylation was scored as follows: 0, no methylation; 1, low but detectable methylation; 2, ⬃50% methylation; 4, complete methylation. b Numbers correspond to the numbering of promoter CpGs in Fig. 1B. c Expression of TLR2 on mRNA level as determined by RT-PCR or Northern blot (22): ⫹, detectable; ⫹/⫺, low level; ⫺, undetectable. The Journal of Immunology 13. 14. 15. 16. 17. 18. 19. 20. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 89:1827. Chaudhary, P. M., C. Ferguson, V. Nguyen, O. Nguyen, H. F. Massa, M. Eby, A. Jasmin, B. J. Trask, L. Hood, and P. S. Nelson. 1998. Cloning and characterization of two Toll/interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans. Blood 91:4020. Rock, F. L., G. Hardiman, J. C. Timans, R. A. Kastelein, and J. F. Bazan. 1998. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA 95:588. Musikacharoen, T., T. Matsuguchi, T. Kikuchi, and Y. Yoshikai. 2001. NF-B and STAT5 play important roles in the regulation of mouse Toll-like receptor 2 gene expression. J. Immunol. 166:4516. Matsuguchi, T., K. Takagi, T. Musikacharoen, and Y. Yoshikai. 2000. Gene expressions of lipopolysaccharide receptors, Toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood 95:1378. Lin, Y., H. Lee, A. H. Berg, M. P. Lisanti, L. Shapiro, and P. E. Scherer. 2000. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J. Biol. Chem. 275:24255. Eichbaum, Q., D. Heney, D. Raveh, M. Chung, M. Davidson, J. Epstein, and R. A. Ezekowitz. 1997. Murine macrophage mannose receptor promoter is regulated by the transcription factors PU.1 and SP1. Blood 90:4135. Feng, X., S. L. Teitelbaum, M. E. Quiroz, S. L. Cheng, C. F. Lai, L. V. Avioli, and F. P. Ross. 2000. Sp1/Sp3 and PU.1 differentially regulate 5 integrin gene expression in macrophages and osteoblasts. J. Biol. Chem. 275:8331. Hauses, M., R. R. Tonjes, and M. Grez. 1998. The transcription factor Sp1 regulates the myeloid-specific expression of the human hematopoietic cell kinase (HCK) gene through binding to two adjacent GC boxes within the HCK promoter-proximal region. J. Biol. Chem. 273:31844. Zhang, D. E., C. J. Hetherington, D. A. Gonzalez, H. M. Chen, and D. G. Tenen. 1994. Regulation of CD14 expression during monocytic differentiation induced with 1␣,25-dihydroxyvitamin D3. J. Immunol. 153:3276. Matsuguchi, T., T. Musikacharoen, T. Ogawa, and Y. Yoshikai. 2000. Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J. Immunol. 165:5767. Visintin, A., A. Mazzoni, J. H. Spitzer, D. H. Wyllie, S. K. Dower, and D. M. Segal. 2001. Regulation of Toll-like receptors in human monocytes and dendritic cells. J. Immunol. 166:249. Razin, A. 1998. CpG methylation, chromatin structure and gene silencing: a three-way connection. EMBO J. 17:4905. Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285:736. Aliprantis, A. O., R. B. Yang, D. S. Weiss, P. Godowski, and A. Zychlinsky. 2000. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J. 19:3325. Downloaded from http://www.jimmunol.org/ by guest on August 3, 2017 21. 2001. Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acidinduced NF-B translocation. J. Biol. Chem. 276:22041. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C. J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Tolllike receptor 2. J. Biol. Chem. 274:17406. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of Gramnegative and Gram-positive bacterial cell wall components. Immunity 11:443. Underhill, D. M., A. Ozinsky, K. D. Smith, and A. Aderem. 1999. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc. Natl. Acad. Sci. USA 96:14459. Jones, B. W., T. K. Means, K. A. Heldwein, M. A. Keen, P. J. Hill, J. T. Belisle, and M. J. Fenton. 2001. Different Toll-like receptor agonists induce distinct macrophage responses. J. Leukocyte Biol. 69:1036. Osborn, L., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor ␣ and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor B. Proc. Natl. Acad. Sci. USA 86:2336. Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. USA 97:13766. Werts, C., R. I. Tapping, J. C. Mathison, T. H. Chuang, V. Kravchenko, G. Saint, I, D. A. Haake, P. J. Godowski, F. Hayashi, A. Ozinsky, et al. 2001. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat. Immunol. 2:346. Tabeta, K., K. Yamazaki, S. Akashi, K. Miyake, H. Kumada, T. Umemoto, and H. Yoshie. 2000. Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts. Infect. Immun. 68:3731. Yang, R. B., M. R. Mark, A. Gray, A. Huang, M. H. Xie, M. Zhang, A. Goddard, W. I. Wood, A. L. Gurney, and P. J. Godowski. 1998. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395:284. Muzio, M., D. Bosisio, N. Polentarutti, G. D’amico, A. Stoppacciaro, R. Mancinelli, C. van’t Veer, G. Penton-Rol, L. P. Ruco, P. Allavena, and A. Mantovani. 2000. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164:5998. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156. Rehli, M., A. Poltorak, L. Schwarzfischer, S. W. Krause, R. Andreesen, and B. Beutler. 2000. PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J. Biol. Chem. 275:9773. Frommer, M., L. E. McDonald, D. S. Millar, C. M. Collis, F. Watt, G. W. Grigg, P. L. Molloy, and C. L. Paul. 1992. A genomic sequencing protocol that yields 5637